Sharekhan

Hester Biosciences Ltd

Wed 21/05/2025,15:41:0 | NSE : HESTERBIO

₹ 1760.00-25.50 (-1.43%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1789.60

Previous Close

₹ 1785.50

Volume

5481

Mkt Cap ( Rs. Cr)

₹1497.21

High

₹ 1805.90

Low

₹ 1744.60

52 Week High

₹ 3379.00

52 Week Low

₹ 1242.95

Book Value Per Share

₹ 354.81

Dividend Yield

0.39

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Hester Biosciences Ltd

Your Vote -

Buy

88.89%

Hold

2.78%

Sell

8.33%

88.89%

36 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Hester Biosciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Hester Biosciences L - Analysts/Institutional Investor Meet/Con. Call Updates

    12 May 2025, 4:21PM Hester Biosciences Limited has informed the Exchange about Transcript
  • Hester Biosciences L - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    12 May 2025, 4:18PM Transcript of Earnings Conference Call held on 9 May 2025
  • Hester Biosciences L - Copy of Newspaper Publication

    10 May 2025, 9:50AM Hester Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
  • Hester Biosciences L - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    9 May 2025, 3:20PM Audio recording of the Earnings Conference Call
  • Hester Biosciences L - Analysts/Institutional Investor Meet/Con. Call Updates

    9 May 2025, 3:20PM Hester Biosciences Limited has informed the Exchange about Link of Recording
  • Hester Biosciences L Q4 net profit up 29.74% at Rs 9.64 cr

    9 May 2025, 12:30PM The company reported standalone net profit of Rs 9.64 crore for the quarter ended March 31, 2025 as compared to Rs 7.43 crore in the same period last
  • Hester Biosciences L - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    9 May 2025, 12:17PM HESTER BIOSCIENCES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer
  • Hester Biosciences L - Outcome of Board Meeting-XBRL

    9 May 2025, 12:15PM HESTER BIOSCIENCES LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 09-May-2025 for Dividend
  • Hester Biosciences L - Press Release

    9 May 2025, 12:09PM Hester Biosciences Limited has informed the Exchange regarding a press release dated May 09, 2025, titled ""20250509 Q4 & FY25 Press Release"".
  • Hester Biosciences L - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    9 May 2025, 12:08PM 20250509 Q4 & FY25 Press Release
  • Hester Biosciences L - Appointment Of Secretarial Auditors Of The Company

    9 May 2025, 12:05PM Appointment of Secretarial Auditors of the Company
  • Hester Biosciences L - Appointment

    9 May 2025, 12:05PM Hester Biosciences Limited has informed the Exchange regarding Appointment of Shah & Shah Associates as Other of the company w.e.f. April 01, 2025.
  • Hester Biosciences L - Corporate Action-Board approves Dividend

    9 May 2025, 12:00PM Board approves and recommend the Final Dividend of INR 7 per shares
  • Hester Biosciences L - Dividend

    9 May 2025, 11:59AM Hester Biosciences Limited has informed the Exchange that Board of Directors at its meeting held on May 09, 2025, recommended Final Dividend of Rs. 7
  • Hester Biosciences L - Financial Results Q4 & FY 25

    9 May 2025, 11:52AM Financial Results Q4 & FY25
  • Hester Biosciences L - Outcome of Board Meeting

    9 May 2025, 11:47AM Hester Biosciences Limited has informed the Exchange regarding Outcome of Board Meeting held on May 09, 2025.
  • Hester Biosciences L - Dividend

    9 May 2025, 11:43AM Hester Biosciences Limited has informed the Exchange that Board of Directors at its meeting held on May 09, 2025, recommended Final Dividend of 7 per
  • Hester Biosciences L - Board Meeting Outcome for Outcome Of Board Meeting

    9 May 2025, 11:42AM Outcome of Board Meeting
  • Hester Biosciences L - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    2 May 2025, 4:50PM This is to inform you that, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform tha
  • Hester Biosciences L - Analysts/Institutional Investor Meet/Con. Call Updates

    2 May 2025, 4:50PM Hester Biosciences Limited has informed the Exchange about Schedule of meet
  • Hester Biosciences L - Board Meeting Intimation

    2 May 2025, 9:47AM HESTER BIOSCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 09-May-2025 to consider and approve the Yearly Audited Financia
  • Hester Biosciences L - Board Meeting Intimation for Financial Results

    2 May 2025, 9:45AM Hester Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2025 ,inter alia, to consider a
  • Hester Biosciences L - Disclosure under SEBI Takeover Regulations

    28 Apr 2025, 1:09PM Hester Biosciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Su
  • Hester Biosciences L - Reply To Clarification Sought On Price Movement In Company'S Securities

    26 Apr 2025, 1:13PM Reply to the email dated 25 April 2025 vide reference number L/SURV/ONL/PV/AJ/2025-2026/2960 seeking clarification regarding the recent movement in th
  • Hester Biosciences L - Price movement

    26 Apr 2025, 1:07PM Significant movement in price has been observed in Hester Biosciences Limited. The Exchange, in order to ensure that investors have latest relevant in
  • Hester Biosciences L - Clarification sought from Hester Biosciences Ltd

    25 Apr 2025, 6:33PM The Exchange has sought clarification from Hester Biosciences Ltd on April 25, 2025, with reference to significant movement in price, in order to ensu
  • Hester Biosciences L - Price movement

    25 Apr 2025, 6:05PM Significant movement in price has been observed in Hester Biosciences Limited. The Exchange, in order to ensure that investors have latest relevant in
  • Hester Biosciences L has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    8 Apr 2025, 11:00AM As of March 2025, 53.73% is owned by Promoters and 46.27% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 44.28% and Fore
  • Hester Biosciences L - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Apr 2025, 10:04AM Confirmation Certificate for the quarter ended 31 March 2025
  • Hester Biosciences L - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Apr 2025, 10:02AM Hester Biosciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Hester Biosciences L - Trading Window-XBRL

    26 Mar 2025, 9:57AM HESTER BIOSCIENCES LIMITED has informed the Exchange about Closure of Trading Window
  • Hester Biosciences L - Trading Window

    26 Mar 2025, 9:56AM Hester Biosciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulation
  • Hester Biosciences

    29 Dec 2022 , 10:49AM Hester Biosciences Ltd will develop and commercialize the low pathogenic avian influenza inactivated vaccine for poultry as the company has signed an agreement to acquire the indigenously developed technology from Indian Council of Agricultural Research - National Institute of High Security Animal Diseases (ICAR-NIHSAD), for the development and commercialization of the Low Pathogenic Avian Influenza (H9N2 strain) Inactivated Vaccine for poultry. Hester has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals. Besides supplying the vaccine within India, Hester intends to export this vaccine to African and Asian countries through its own distribution network, where the demand for this vaccine has already been established. Our view: It’s a positive read through for the stock
  • Hester acquires technology from ICAR – NIHSAD

    28 Dec 2022 , 11:36AM Hester acquires technology from ICAR – NIHSAD to develop a Low Pathogenic Avian Influenza (H9N2 strain) Inactivated Vaccine for poultry
  • Hester Biosciences gets Rs. 600 million grant to make COVID vaccine

    8 Apr 2022 , 1:46PM Board approves the execution of Grantin-Aid Letter Agreement for grant of Rs. 600 million
  • Hester Biosciences forays into Pet Care sector with New Products

    22 Mar 2022 , 1:58PM Hester Biosciences will expand into the rapidly growing Pet Care sector this April
  • Hester Biosciences

    30 Dec 2021 , 11:36AM To commence supplies of drug substance for Bharat Biotech’s Covid-19 vaccine Covaxin by April 2022. The company is constructing a biosafety level -3 facility at its Mehsana plant with an investment of Rs 100, which will enable it to produce 5-7 million doses of the Covaxin drug substance every month. Earlier in May 2021 Hester has entered in to an agreement with Bharat Biotech to make drug substance for Covaxin. As per the agreement, Hester will supply the drug substance to Bharat Biotech which will then do the fill-finish at its facilities. Positive read thru
  • Cadila, Hester Biosceinces

    27 Dec 2021 , 1:27PM The Government of India has announced the commencement of the vaccination for children in the age group of 15-18 years. For this age group two vaccines – Cadila’s ZyCov-D and Covaxin have approved by the drug regulator and hence positive for Cadila and Hester Biosciences, as it has a tie up with Bharat Biotech for manufacturing Covaxin
  • Hester signs two agreements with ICAR-IVRI

    8 Apr 2021 , 12:36PM Hester Biosciences acquires technology for production of classical swine fever & sheep pox vaccines
  • IIT Guwahati collaborates with Hester Biosciences

    29 Apr 2020 , 11:37AM IIT Guwahati collaborates with Hester Biosciences Limited to develop vaccine against COVID-19
  • Hester Biosciences board to raise fund up to Rs. 150 crore

    18 Dec 2019 , 11:31AM Hester Biosciences board approves raising up to Rs. 150 crore via QIP or preferential allotment
  • Hester Biosciences to invest in African subsidiary

    9 Jun 2017 , 10:56AM Hester Biosciences plans to invest $3 million in its wholly-owned subsidiary in Africa - Hester Biosciences Africa Limited, Tanzania

Key fundamentals

Evaluate the intrinsic value of Hester Biosciences Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 443.354 446.276 456.704 390.347 241.967
Liabilities 443.354 446.276 456.704 390.347 241.967
Equity 8.507 8.507 8.507 8.507 8.507
Gross Profit 50.944 47.341 54.886 60.569 71.993
Net Profit 31.842 27.159 32.342 39.517 39.901
Cash From Operating Activities 63.971 42.812 33.362 15.905 40.071
NPM(%) 11.11 9.52 12.73 18.01 19.13
Revenue 286.466 285.155 254 219.351 208.477
Expenses 235.522 237.814 199.114 158.782 136.484
ROE(%) 10.54 8.99 10.71 13.09 13.21

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
7 70 0.4 1645.6
22 Aug 2024 6 60 0.4 1735.8
13 Sep 2023 8 80 0.4 1723.7
11 Aug 2022 10 100 0.4 2276.75
05 Aug 2021 10 100 0.4 2754.9
27 Aug 2020 6.6 66 0.4 1254
18 Jul 2019 7 70 0.4 1531.15
09 Nov 2018 2 20 0.4 1156.35
30 Aug 2018 2 20 0.4 1345.85
02 Aug 2018 6 60 0.4 1529.6
20 Jul 2017 2.3 23 0.4 879.2
03 Nov 2016 3 30 0.4 756.75
21 Jul 2016 1.1 11 0.4 648.05
17 Mar 2016 3 30 0.4 425.45
10 Sep 2015 3.1 31 0.4 548.4

Peers

Other companies within the same industry or sector that are comparable to Hester Biosciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.15 -0.84 26.88 1010.46 301.39 0.62
Lotus Eye Hospital and Institute Ltd 74.06 0.78 308.58 3681.98 14.01 0.68
Vaishali Pharma Ltd 12.85 -1.15 428.33 1897.84 2.76 0.00
Astec Lifesciences Ltd 701.25 -1.59 0.00 3471.79 -687.11 0.00

Company Info

YEAR EVENTS 1987 - The Company was incorporated in 29th April as a Private Limited Company. It was subsequently coverted into a Public Limited Company on 1st November 1993. - Hester Pharmaceuticals Limited is an existing porfit amking company engaged in the business of marketing and distribution of veterinary and pharmaceutical products viz, Animal Health prdoducts, Poultry Vaccines, Poultry Diagnostic, Laboratory Kits and Reagents. - HPL represents many international companies for marketing veterinary products. Some of these companies are GHEN CORPORATION, JAPAN for animal and agro based products, MARINE BIOLOGICAL LABORATORIES, USA for poultry vaccines, IDEXX CORPORATION, USA for Laboratory Kits & Reagents, INTERNATIONAL DIAGNOSTIC SYSTEMS CORPORATION, USA for animal kits for detection of drug abuse, BIOGALGALTED LABORATORIES, ISRAEL for Poultry Diagnostic Kits and KEMIN EUROPA, BELGIUM for feed Additives and Disinfectants. - The Company has been promoted by Mr. Rajiv D. Gandhi, his brother Mr. Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. 1994 - The company came out with a Public Issue of 21,40,000 No. of equity shares of Rs. 10/- each for cash at par aggregating, Rs. 214.00 lacs on the 17th August to part finance the company's project to manufacture poultry vaccines, to enlist the shares of the company on the stock exchanges at Ahmedabad, Bombay and to meet the expenses of the Issue. 1997 - The company has created an excellent manufacturing facility to produce Animal Vaccines. 1999 - Mr. Vinod Agarwala, Director, resigned from the Board, due to personal reasons. Mr. A.C. Patel was appointed as a Nominee Director of Gujarat Industrial Investment Corporation Limited in place of Mr. C.R. Damani. Mr. Ravin Gandhi and Ms. Bela Gandhi have been appointed as additional Directors in the Company. 2000 - Ahmedabad-based Hester Pharmaceuticals Ltd. an Indo-american joint venture company manufacturing the largest range of poultry vaccines in India has entered into a contract manufacturing agreement with the Tokyo-based Sinsui Inc. 2004 - delisted from Ahmedabad Stock Exchange wef October 15, 2004. 2008 - Company name has been changed from Hester Pharmaceuticals Ltd to Hester Biosciences Ltd. -Hester Biosciences Ltd Issues Rights in the Ratio of 2:5 2010 - Hester Biosciences Ltd has appointed Mr. Vishvesh Patel as a Non-Executive Independent Director of the Company, w.e.f. May 23, 2010, by the Board of Directors of the Company in their meeting held on May 23, 2010. 2011 -Hester Biosciences has recommended a Dividend of Rs. 3.50 per equity share of Rs. 10 each (35%) 2012 -Hester entered into a Business Transfer Agreement (BTA) with Innoves Animal Health Private Limited, a Delhi based company involved in the marketing of Large Animal Health Products for the dairy -Hester Biosciences has given the Bonus in the Ratio of 1:2 2013 -Hester Biosciences L - WHO GMP Certification awarded to Hester Launching of Bivalent Marek's Disease Live Vaccine containing 2014 -Hester Biosciences board approves scheme of amalgamation -The Company has recommended a dividend of Rs. 2.00 per equity share of Rs. 10 each (20%) for the financial year 2013-14 2015 - "Hester Biosciences launches PPR vaccine and Goat Pox vaccine". 2020 - launch of the thermo-tolerant PPR Vaccine by Hester Nepal". 2021 - Hester to produce and commercialize Classical Swine Fever Vaccine and Sheep Pox Vaccine

YEAR EVENTS 1987 - The Company was incorporated in 29th April as a Private Limited Company. It was subsequently coverted into a Public Limited Company on 1st November 1993. - Hester Pharmaceuticals Limited is an existing porfit amking company engaged in the business of marketing and distribution of veterinary and pharmaceutical products viz, Animal Health prdoducts, Poultry Vaccines, Poultry Diagnostic, Laboratory Kits and Reagents. - HPL represents many international companies for marketing veterinary products. Some of these companies are GHEN CORPORATION, JAPAN for animal and agro based products, MARINE BIOLOGICAL LABORATORIES, USA for poultry vaccines, IDEXX CORPORATION, USA for Laboratory Kits & Reagents, INTERNATIONAL DIAGNOSTIC SYSTEMS CORPORATION, USA for animal kits for detection of drug abuse, BIOGALGALTED LABORATORIES, ISRAEL for Poultry Diagnostic Kits and KEMIN EUROPA, BELGIUM for feed Additives and Disinfectants. - The Company has been promoted by Mr. Rajiv D. Gandhi, his brother Mr. Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. 1994 - The company came out with a Public Issue of 21,40,000 No. of equity shares of Rs. 10/- each for cash at par aggregating, Rs. 214.00 lacs on the 17th August to part finance the company's project to manufacture poultry vaccines, to enlist the shares of the company on the stock exchanges at Ahmedabad, Bombay and to meet the expenses of the Issue. 1997 - The company has created an excellent manufacturing facility to produce Animal Vaccines. 1999 - Mr. Vinod Agarwala, Director, resigned from the Board, due to personal reasons. Mr. A.C. Patel was appointed as a Nominee Director of Gujarat Industrial Investment Corporation Limited in place of Mr. C.R. Damani. Mr. Ravin Gandhi and Ms. Bela Gandhi have been appointed as additional Directors in the Company. 2000 - Ahmedabad-based Hester Pharmaceuticals Ltd. an Indo-american joint venture company manufacturing the largest range of poultry vaccines in India has entered into a contract manufacturing agreement with the Tokyo-based Sinsui Inc. 2004 - delisted from Ahmedabad Stock Exchange wef October 15, 2004. 2008 - Company name has been changed from Hester Pharmaceuticals Ltd to Hester Biosciences Ltd. -Hester Biosciences Ltd Issues Rights in the Ratio of 2:5 2010 - Hester Biosciences Ltd has appointed Mr. Vishvesh Patel as a Non-Executive Independent Director of the Company, w.e.f. May 23, 2010, by the Board of Directors of the Company in their meeting held on May 23, 2010. 2011 -Hester Biosciences has recommended a Dividend of Rs. 3.50 per equity share of Rs. 10 each (35%) 2012 -Hester entered into a Business Transfer Agreement (BTA) with Innoves Animal Health Private Limited, a Delhi based company involved in the marketing of Large Animal Health Products for the dairy -Hester Biosciences has given the Bonus in the Ratio of 1:2 2013 -Hester Biosciences L - WHO GMP Certification awarded to Hester Launching of Bivalent Marek's Disease Live Vaccine containing 2014 -Hester Biosciences board approves scheme of amalgamation -The Company has recommended a dividend of Rs. 2.00 per equity share of Rs. 10 each (20%) for the financial year 2013-14 2015 - "Hester Biosciences launches PPR vaccine and Goat Pox vaccine". 2020 - launch of the thermo-tolerant PPR Vaccine by Hester Nepal". 2021 - Hester to produce and commercialize Classical Swine Fever Vaccine and Sheep Pox Vaccine

Read More

Parent Organisation

Hester Biosciences Ltd.

Founded

29/04/1987

Managing Director

Mr.Rajiv Gandhi

NSE Symbol

HESTERBIOEQ

FAQ

The current price of Hester Biosciences Ltd is ₹ 1760.00.

The 52-week high for Hester Biosciences Ltd is ₹ 1805.90 and the 52-week low is ₹ 1744.60.

The market capitalization of Hester Biosciences Ltd is currently ₹ 1497.21. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Hester Biosciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Hester Biosciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Hester Biosciences Ltd shares.

The CEO of Hester Biosciences Ltd is Mr.Rajiv Gandhi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT